0.00Open0.00Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover218.58%IV-48.04%PremiumMay 16, 2025Expiry Date6.49Intrinsic Value100Multiplier16DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7285Delta0.0530Gamma1.85Leverage Ratio-0.0617Theta-0.0066Rho-1.35Eff Leverage0.0095Vega
Liquidia Stock Discussion
Fast-Track FDA Review: YUTREPIA's Dual-Disease Treatment Advances After Key Acceptance
Liquidia | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Paul B. Manning(7.9%),BKB Growth Investments, LLC(1.0%), etc.
Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
Dow Jones· 1 min ago
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
Dow Jones· 19 mins ago🥂💵
No comment yet